The EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and ...

AbbVie says that Elahere is the first and only folate receptor alpha (FRɑ)-directed antibody drug conjugate (ADC) medicine ...

The immunohistochemistry test detects the folate receptor 1 protein, which is over-expressed in most ovarian cancers.

AbbVie has announced the European Commission (EC) has granted marketing authorization for ELAHERE (mirvetuximab soravtansine) ...

AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...

Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, ...

NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate ...

Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancer; Allarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate st ...

VNS Health Total (HMO D-SNP)­ has earned five stars from the New York State Department of Health (NYSDOH), and received the highest Quality Incentive rating of any dual-eligible Medicaid Advantage ...

Trump Suggests Use of Emergency Powers and the Military for Deportations Donald Trump addressed his plans for mass deportations in a social media post. He is expected to interview candidates for ...

A view of the new Beijing Stock Exchange at the Financial Street, in Beijing, China, November 15, 2021. REUTERS/Tingshu Wang/File Photo Asian stocks rose on Tuesday while U.S. bond yields and the ...